Your trusted source for investing success

Tag: abbott

Q Biomed Inc. Adds Nuclear Medicine Industry Veteran to Commercialization Team

Q Biomed Inc. Adds Nuclear Medicine Industry Veteran to Commercialization Team

Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company, announced today that Christopher Manuele will join the Strontium 89 Chloride commercialization team.
Mr. Manuele is a results-oriented, innovative executive with thirty-five years of comprehensive US and International expertise in nuclear medicine and medical isotope production. A long-time veteran of Amersham Health and

BioSig Technologies Provides Shareholder Update

BioSig Technologies Provides Shareholder Update

BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today provided a shareholder update and highlighted the company’s recent achievements it has reached during the first part of

BioSig Technologies Completes Private Placement

BioSig Technologies Completes Private Placement

BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced the Company closed a private placement with proceeds of $4,349,953.50. Laidlaw & Co (UK) Ltd. in New

BioSig Technologies Announces Strategic Partnership with Mayo Clinic

BioSig Technologies Announces Strategic Partnership with Mayo Clinic

BioSig Technologies (OTCQB:BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced it has signed a ten-year strategic agreement with Mayo Clinic and Mayo Clinic Ventures. This new, expanded collaboration

Abbott offers EU concessions over $25 billion St. Jude deal

Reuters reported that Abbott Laboratories (NYSE:ABT) has offered concessions for its $25 billion bid for St. Jude Medical (NYSE:STJ).

As quoted in the article:
The move pushed back the European Commission’s decision on the deal to Nov. 21 from Nov. 9, according to a filing on the EU competition enforcer’s website on

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network